LEO Pharma gears for growth with senior leadership changes
LEO Pharma is excited to announce strategic leadership changes to bolster growth, further professionalize the organization, and strengthen its commitment to strategy and transformation. Kristian Sibilitz has been appointed as the new Executive Vice President (EVP) of Technical Development and Supply and will join the Global Leadership Team on December 1, 2024. Effective immediately, Jean Monin, EVP of Thrombosis, and Anne Jensen, Vice President (VP) of Strategy, will also join the Global Leadership Team. Additionally, Anders Monrad Rendtorff will join as the new head of Global Communications.
Ballerup, 7 November 2024 - With the announcement of three new members to the Global Leadership Team and a new head of Global Communications, LEO Pharma is taking another important step towards further professionalizing the organization and realizing its strategy to become the leader in medical dermatology.
Kristian Sibilitz will take up the position as EVP, Technical Development and Supply and member of the Global Leadership Team on 1 December 2024. He replaces Sven Hauptmann, who has decided to resign from LEO Pharma to join a Swiss company. Sven Hauptmann will leave by 30 November 2024.
Kristian Sibilitz brings extensive experience to LEO Pharma, having spent over 19 years at H. Lundbeck A/S in various leadership roles within Product Development and Supply. Currently, he is the Senior Vice President (SVP) of Pharmaceutical Production and Supply Chain, overseeing manufacturing, packaging, supply chain planning, and global distribution. A Danish citizen, Kristian holds a Master of Science in Supply Chain Management from the Technical University of Denmark, DTU.
CEO, Christophe Bourdon said: “We are pleased to welcome Kristian to the Global Leadership Team, where his extensive expertise and strong track record will be highly valued. At the same time, I would like to extend my sincere gratitude to Sven for his remarkable efforts in delivering safe and innovative products to patients, which have been unparalleled.”
In addition, Jean Monin, EVP of thrombosis, and Anne Jensen, VP, who leads LEO Pharma's strategy team, will also join the Global Leadership Team.
CEO Christophe Bourdon said, “I am delighted to welcome Jean and Anne to the Global Leadership Team. Jean has demonstrated proven success as a commercial leader, driving excellent results across the Thrombosis Global Business Unit in recent quarters. With Jean’s commercial expertise and Anne’s achievements in sharpening LEO Pharma’s strategy, they are both well-positioned to enhance our strategic execution and optimize LEO Pharma’s ability to capitalize on both present and future opportunities.”
Additionally, Anders Monrad Rendtorff will join LEO Pharma as SVP for Global Communications. Anders Monrad Rendtorff brings extensive experience to LEO Pharma, having worked for large, listed companies such as Coloplast and Vestas.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, mobile +45 3050 2014
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of approx. 4,000 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 17:45:38 CET | Pressemeddelelse
The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for 16 weeks in the DELTA 1 2 phase 3 trials.(1) Late-breaking presentation showcased that delgocitinib cream produced a deep, consistent and/or maintained response in a subgroup of patients with moderate to severe Chronic Hand Eczema (CHE).(1) Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe CHE.(2)
Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors5.3.2025 10:00:00 CET | Pressemeddelelse
At LEO Pharma’s Annual General Meeting 5 March 2025, Liisa Hurme, President and CEO of Orion Corporation, and Mark Levick, former EU medicines regulator and CEO of Alvotech, were elected as independent members of the Board of Directors. Liisa Hurme brings over 20 years of experience in the chemical and healthcare industries, with expertise in R&D, business development, global supply chains, and operations. She joined Orion Corporation in 1999 and became President and CEO in 2022. Liisa also chairs the Board at the Chemical Industry Federation of Finland and has served on various company and industry boards. She holds a doctorate in biochemistry from the University of Helsinki. Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. His expertise was gained through a successful career as a practicing specialist physician in Australia and the UK, before leading global R&D groups at GlaxoSmithKline and Novartis in the
LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation26.2.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 26 February, 2025 – LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its profitability targets and to achieve its long-term strategic objectives. “2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA. A major highlight in 2024 was the approval and launch of our pioneering innovative topical Anzupgo® for chronic hand eczema (CHE). Additionally, we have strengthened our pipeline and successfully implemented efficiency initiatives set to substantially further improve our financial performance in 2025 and return LEO Pharma to a positive net result. With our innovative portfolio demonstrating significant commercial potential, and by maintaining financial discipline, delivering consistent high growth, and building an attractive pipeline, we are creating
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases5.2.2025 09:00:00 CET | Pressemeddelelse
Partners form non-exclusive collaboration to expand research efforts and develop new treatments for Epidermolysis Bullosa (EB). The partnership leverages DEBRA Research’s focus on patient care and pharma experience and LEO Pharma’s extensive medical dermatology experience. Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit organization dedicated to advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB) and LEO Pharma, a global leader in medical dermatology, today announced a non-exclusive strategic partnership. This collaboration aims to enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for EB. The partners are committed to driving transformative progress for EB patients and their families, and to deliver innovative medicines for this serious skin disease with no approved treatment options. “We are pleased to announce our non-exclusive partne
LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)4.2.2025 14:00:00 CET | Pressemeddelelse
The phase 3 clinical trial (DELTA TEEN) with Anzupgo® in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate, achieved primary and all key secondary endpoints compared to cream vehicle.(1) CHE can significantly affect the quality of life for adolescent patients.(2) There are currently no approved treatment options specifically indicated for moderate to severe CHE in the adolescent patient population.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum